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Multiple Endocrine Neoplasia type 2A (MEN-2a) is a rare disease associated with tumors of endocrine organs. Presentation
most commonly is with medullary thyroid cancer and infrequently with other complaints. Pituitary adenoma has been seen
coincidentally with this disease very rarely. Presented is a case of coincident MEN-2a with a symptomatic pituitary adenoma
and an asymptomatic pheochromocytoma. A brief review is also provided.
1.Introduction
Pheochromocytoma is a physiologically active tumor of the
adrenal gland that occurs in isolation or in association with
Multiple Endocrine Neoplasia type 2a (MEN-2a). Rarely
is pheochromocytoma the presenting disease process in
MEN-2a and even more rarely is it associated with pituitary
macroadenoma. We present a case of MEN-2a presenting in
a highly unusual manner that brings into question the need
for more extensive workup prior to treatment for pheochro-
mocytoma.
2.CasePresentation
A 62-year-old white male presented with right abdominal
and ﬂank pain of gradual onset over several months. He
had a history of hypertension controlled with atenolol only
and had no history of paroxysmal hypertensive episodes.
Workup revealed a 13cm right adrenal mass by CT
(Figure 1) which on T2-weighted MRI was high attenuating
in nature (Figure 2). Due to suspicion for pheochromo-
cytoma, serum and urinary metanephrines were obtained.
Serum Normetanephrine was 7086µg/mL and serum me-
tanephrine was 538µg/mL. Urinary Normetanephrine was
29,653µg/mL (normal 75–375µg/mL) and metanepherine
was 2560µg/mL (normal 24–96µg/mL). Prior to planned
right open adrenalectomy, blockade was begun with 10mg
daily of phenoxybenzamine.
Open adrenalectomy was complicated with intraopera-
tive hypertensive crisis, diﬃcult exposure due to the size of
the tumor, and ultimately right nephrectomy in order to
facilitate removal of the tumor. Adherence to the inferior
venacava(IVC)necessitated partialresection oftheIVCwith
primary closure. Once the tumor vasculature was isolated,
hypotension ensued requiring pressor support. The patient
remained intubated postoperatively and was extubated on
postoperative day one. Later the same day, the patient
complained of headache and left sided visual ﬁeld loss. Exam
conﬁrmed left lateral hemianopsia. These ﬁndings were not
present preoperatively based on history and physical exam.
MRI of the head was performed to evaluate visual
ﬁeld defect and a 1cm pituitary macroadenoma was found
compressing the optic chiasm (Figure 3). At this point full
endocrine evaluation was obtained including all pituitary
hormones, thyroid hormones, parathyroid hormone, and
calcitonin. Also evaluation of the RET proto-oncogene
demonstrated a missense mutation(C618S)i ne x on10ofth e
gene. Parathyroid hormone was elevated at 155pg/mL and2 ISRN Oncology
Figure 1: CT of the abdomenshowingan adrenal massadherent to
the IVC.
Figure 2: T2-Weighted MRI of the abdomen demonstrating high-
attenuation characteristic of pheochromocytoma.
calcitonin was slightly above normal at 116pg/mL. Sono-
gram of the thyroid demonstrated bilateral involvement of
thethyroidwithcysticnodules.Fineneedleaspiration(FNA)
suggested medullary thyroid carcinoma and so thyroidec-
tomy was performed along with subtotal parathyroidectomy.
Pathology of the adrenal specimen demonstrated pheo-
chromocytoma with focal capsular penetration but tumor-
free margins (Figure 4). Thyroid pathology was bilateral
medullary thyroid carcinoma pT1 with no clinical nodes
or metastases. The pituitary adenoma was treated with
transsphenoidalresection,howeverthepatientdidnotregain
visual function in followup. At 12 months followup he
remains tumor-free and normotensive on atenolol.
3.DiscussionofDiagnosis
Multiple Endocrine Neoplasia syndrome type 2a (MEN-2a)
is an autosomal dominant hereditary syndrome caused
by mutation of the tyrosine kinase RET proto-oncogene
on chromosome 10q11.2. The hallmark of the disease is
medullary thyroid cancer (MTC) which occurs in nearly
100% of cases [1]. Pheochromocytoma is identiﬁed in 30–
50% of patients with MEN-2a. Hyperparathyroidism occurs
in 20% of patients and is usually mild and manifests as only
Figure 3: MRI of the brain showing pituitary macroadenoma
compressing the optic chiasm.
Figure 4
a slight elevation of serum calcium [2]. Most cases present
with MTC primarily and through screening and followup
are found to have other associated tumors. Only 15% of
MEN-2a patient present with pheochromocytoma as the
primary complaint and 25% have concomitant MTC and
pheochromocytoma. Most commonly pheochromocytoma
is discovered at a mean of 10 years after the MTC is discov-
ered and treated [1].
Treatment of MTC is typically total thyroidectomy with
bilateral neck dissection for lymphadenectomy. Screening
for pheochromocytoma is performed yearly with urinary
metanephrine assessment. Unilateral pheochromocytoma is
commonly amenable to laparoscopic resection [3]. Partial
adrenalectomy for small tumors has been described and
has a similar complication rate to total adrenalectomy. This
approach may be considered in patients with MEN-2a due
to their recurrence rate of 10–20% [1, 4]. Management of
hyperparathyroidism depends on the patient’s preoperative
calcium and parathyroid hormone levels. If the patient
is eucalcemic, then only removal of obviously enlarged
parathyroid glands should be done and otherwise the
parathyroid should be spared [5].ISRN Oncology 3
Surgery for large pheochromocytoma can be a diﬃ-
cult and dangerous task. Small series have shown little
diﬀerence in complication rate between laparoscopic and
open approach, however the risk of open conversion due
to intraoperative bleeding increases for tumors greater than
6cm [3, 6]. In the described case, where adherence to
surrounding structures and obscurement of blood supply
were felt to be problematic, laparoscopy was not attempted.
Even so, extremes of blood pressure and surgical diﬃculty
were encountered which likely altered blood ﬂow dynamics
to the already compromised optic chiasm intraoperatively
andbroughttolightthediagnosis ofpituitaryadenoma.This
prompted the workup for MEN and ultimately the diagnosis
of the patient’s most mortal disease—his thyroid cancer.
Pheochromocytoma are most commonly sporadic, how-
ever 10–23% are associated with a familial syndrome.
Workup with CT and/or MRI is recommended for staging
and localization purposes. Scintigraphy using 131I-MIBG
(metaiodobenzylguanidine) is useful to determine the loca-
tion of occult lesions when CT or MRI are unproductive.
There are currently no formal recommendations for workup
of associated malignancies when there is no family history.
Only 5% of patients with pheochromocytoma present with-
out symptoms, however in patients with MEN-2a, 50% will
be asymptomatic [7]. This may be a characteristic of the
disease or it may reﬂect the impact of screening in this pop-
ulation. More investigation may be warranted to determine
if patients with incidentally discovered pheochromocytoma
warrant workup for a familial cause.
The RET proto-oncogene is a 21 exon gene encoding a
tyrosine kinase receptor that is involved in transduction of
growth and diﬀerentiation signals in developing tissues—
particularly thoseof neuralcrestorigin.RETis strongly asso-
ciated with MEN-2a and patients with a RET mutation have
a nearly 100% chance of developing MTC. Diﬀerent point
mutationsinthisgeneareassociatedwithvarying penetrance
of pheochromocytoma and hyperparathyroidism, lower age
at onset of disease, and likelihood of metastatic disease at
presentation. The mutation in the presented patient, C618S,
indicates substitution of serine for cysteine at point 618
located on exon 10 of the RET gene. This mutation is
associated with a high risk of progression and metastasis
from MTC [8]. Patients screened for this mutation at birth
wouldtypicallyhaveaprophylacticthyroidectomybyageof5
years. Interestingly, this gene is uncommonly associated with
pheochromocytoma [8].
Pituitary adenoma is commonlyassociated with Multiple
Endocrine Neoplasia type 1 (MEN 1), however is not asso-
ciated with MEN-2a. In a recent review, Breckenridge et al.
cited 25 cases of patients with pheochromocytoma and
pituitary macroadenoma from 1964 to 2003 [9]. It is not
certain whether this represents a true association or if these
are merely coincidental. Both pheochromocytoma and pitu-
itary adenoma are believed to arise from neural crest cells.
Schimke’s review of diﬀerent associated tumors favors spo-
radic occurrences over a true association [10]. Although in
the former series, most tumors were functional—including
several presenting with acromegaly, in our patient this was a
nonfunctional pituitary macroadenoma.
More recently, attention has been given to the entity of
familial isolated pituitary adenoma (FIPA). Approximately
5% of pituitary adenomas are hereditary in nature but not
associated with MEN 1 or Carney complex [11]. A recent
series evaluatedpatients with familial pituitary adenoma and
screened for RET mutations and none were found [12].
Mutations of the gene encoding aryl hydrocarbon receptor-
interacting protein (AIP) are found in 20% of patients with
familial pituitary adenoma [13]. AIPhas been shown to have
in vivo interaction with RET, though the precise role of this
interaction is not completely characterized [12]. Vargiolu et
al. evaluated tissue from 28 nonfamilial pituitary adenomas
for mutation of either AIP or RET and none were identiﬁed
[14].
4.Conclusion
Overlap of pituitary adenoma with MEN-2a is a rare occur-
rence and it is unknown to be either sporadic or in asso-
ciation with another syndrome. An interplay between RET
proto-oncogeneand familial isolated pituitary adenoma may
be involved. Asymptomatic pheochromocytoma has a high
association with familial syndrome and may warrant further
scrutiny. This case represents a truly unique presentation of
this very rare phenomenon.
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